Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial

Abstract

BACKGROUND: Randomized trials of postmenopausal hormone therapy have found differing effects on fasting glucose levels. No trial has evaluated the effect of hormone therapy on diabetes incidence. OBJECTIVE: To evaluate the effect of hormone therapy on fasting glucose level and incident diabetes. DESIGN: Randomized, double-blind, placebo-controlled trial. SETTING: 20 U.S. clinical centers. PARTICIPANTS: 2763 postmenopausal women with coronary heart disease who were followed for 4.1 years. At baseline, 734 women had diabetes, 218 women had impaired fasting glucose, and 1811 women were normoglycemic; the 2029 women without diabetes were followed for incident diabetes. INTERVENTION: 0.625 mg of conjugated estrogen plus 2.5 mg of medroxyprogesterone acetate daily, or placebo. MEASUREMENTS: Fasting glucose level was measured at baseline, at year 1, and at the end of the trial. Incident diabetes was defined by self-report of diabetes or disease complication, fasting glucose level of 6.9 mmol/L or greater (> or =126 mg/dL), or initiation of therapy with diabetes medication. RESULTS: Fasting glucose levels increased significantly among women assigned to placebo but did not change among women receiving hormone therapy. The incidence of diabetes was 6.2% in the hormone therapy group and 9.5% in the placebo group (relative hazard, 0.65 [95% CI, 0.48 to 0.89]; P = 0.006). The number needed to treat for benefit to prevent one case of diabetes was 30 (CI, 18 to 103). Changes in weight and waist circumference did not mediate this effect. CONCLUSIONS: In women with coronary disease, hormone therapy reduced the incidence of diabetes by 35%. This observation provides important insights into the metabolic effects of postmenopausal hormones but is insufficient to recommend the use of hormones for secondary prevention of heart disease.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-138-1-200301070-00005

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 61 references

Research works printed but not linked: 10

  1. Lobo RA, 1994, Obstet Gynecol, 84, 987
  2. Kimmerle R, 1999, Menopause, 6, 36
  3. Vehkavaara S, 2000, J Clin Endocrinol Metab, 85, 4663
  4. Andersson B, 1997, J Clin Endocrinol Metab, 82, 638
  5. Friday KE, 2001, J Clin Endocrinol Metab, 86, 48
  6. Colacurci N, 1998, Panminerva Med, 40, 18
  7. 10.1002/(SICI)1520-7560(200001/02)16:1<20::AID-DMRR76>3.0.CO;2-A · doi:10.1002/(sici)1520-7560(200001/02)16:1<20::aid-dmrr76>3.0.co;2-a
  8. Cagnacci A, 1992, J Clin Endocrinol Metab, 74, 1396
  9. O'Sullivan AJ, 1995, J Clin Endocrinol Metab, 80, 1783
  10. Friend KE, 1996, J Clin Endocrinol Metab, 81, 2250

Cited by

See all 633

Metadata

Authors
Kanaya, A. M., Herrington, D., Vittinghoff, E., Lin, F., Grady, D., Bittner, V., Cauley, J. A., & Barrett-Connor, E.
Affiliations
University of Pittsburgh (US)
Venue
Annals of Internal Medicine
Published
2003-01-07
Volume
138
Issue
1
Pages
1-9
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2141759136
Cited by
633
References
61
Citations by year
2026: 9 · 2025: 11 · 2024: 23 · 2023: 25 · 2022: 27 · 2021: 23 · 2020: 20 · 2019: 23 · 2018: 21 · 2017: 27 · 2016: 31 · 2015: 25 · 2014: 25 · 2013: 31 · 2012: 27
FWCI
24.99
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
hormone replacement therapy, conjugated estrogens, medroxyprogesterone acetate, new-onset diabetes, fasting blood glucose, coronary artery disease, diabetes prevention, secondary prevention, impaired fasting glucose
MeSH terms
Aged, Blood Glucose, Coronary Disease, Diabetes Mellitus, Type 2, Double-Blind Method, Estrogens, Conjugated (USP), Fasting, Female, Humans, Middle Aged, Placebos, Risk Factors, Estrogen Replacement Therapy, Incidence, Medroxyprogesterone Acetate, Postmenopause

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.7326/0003-4819-138-1-200301070-00005
The paper
Kanaya, A. M., Herrington, D., Vittinghoff, E., Lin, F., Grady, D., Bittner, V., Cauley, J. A., & Barrett-Connor, E. (2003). Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-138-1-200301070-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.